Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price objective of $41.33 for the company and are anticipating that the company will post $0.35 EPS for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 53 out of 255 based on the ratings given to its competitors.

A number of research firms have weighed in on OPNT. Northland Securities reaffirmed a “buy” rating and set a $42.00 price objective on shares of Opiant Pharmaceuticals in a report on Thursday, November 7th. TheStreet raised Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a report on Friday, August 30th.

NASDAQ OPNT traded up $1.37 during trading on Friday, reaching $14.88. 34,442 shares of the company traded hands, compared to its average volume of 19,627. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $14.65 and its two-hundred day moving average price is $13.94. Opiant Pharmaceuticals has a 1-year low of $9.98 and a 1-year high of $18.23.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Tuesday, November 12th. The technology company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.87. The company had revenue of $20.64 million for the quarter, compared to the consensus estimate of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%. Equities analysts forecast that Opiant Pharmaceuticals will post 0.23 earnings per share for the current fiscal year.

In other news, insider Phil Skolnick sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $15.80, for a total value of $158,000.00. Also, Director Ann L. Macdougall bought 5,000 shares of Opiant Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $13.51 per share, for a total transaction of $67,550.00. Over the last ninety days, insiders have acquired 7,885 shares of company stock worth $106,604 and have sold 27,143 shares worth $401,016. 30.88% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in OPNT. Wedge Capital Management L L P NC acquired a new position in shares of Opiant Pharmaceuticals in the 3rd quarter worth approximately $363,000. Stonepine Capital Management LLC boosted its holdings in shares of Opiant Pharmaceuticals by 7.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock worth $4,180,000 after acquiring an additional 20,574 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Opiant Pharmaceuticals by 1,000.3% in the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock worth $297,000 after acquiring an additional 20,377 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Opiant Pharmaceuticals by 93.5% in the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock worth $276,000 after acquiring an additional 10,045 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Opiant Pharmaceuticals by 24.3% in the 2nd quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock worth $61,000 after acquiring an additional 900 shares in the last quarter. 21.49% of the stock is currently owned by institutional investors and hedge funds.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Article: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.